(19)
(11)EP 2 910 249 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
04.12.2019 Bulletin 2019/49

(21)Application number: 13845181.0

(22)Date of filing:  09.10.2013
(51)Int. Cl.: 
A61K 35/36  (2015.01)
A61P 17/00  (2006.01)
A61P 25/04  (2006.01)
A61P 29/00  (2006.01)
A61K 31/7012  (2006.01)
A61P 19/02  (2006.01)
A61P 27/00  (2006.01)
(86)International application number:
PCT/JP2013/077534
(87)International publication number:
WO 2014/057995 (17.04.2014 Gazette  2014/16)

(54)

EXTRACT AND FORMULATION INCLUDING EXTRACT

EXTRAKT UND FORMULIERUNG MIT DEM EXTRAKT

EXTRAIT, ET PRÉPARATION COMPRENANT CET EXTRAIT


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 10.10.2012 JP 2012225133
25.04.2013 JP 2013092006

(43)Date of publication of application:
26.08.2015 Bulletin 2015/35

(73)Proprietor: Nippon Zoki Pharmaceutical Co., Ltd.
Osaka-shi, Osaka 541-0046 (JP)

(72)Inventors:
  • NAKAZAWA, Yoshitaka
    Kato-shi Hyogo 673-1461 (JP)
  • SHIBAYAMA, Yoji
    Kato-shi Hyogo 673-1461 (JP)
  • NAKAMURA, Ko
    Kato-shi Hyogo 673-1461 (JP)

(74)Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56)References cited: : 
EP-A1- 2 119 444
CA-A1- 2 792 085
WO-A1-2004/039383
JP-A- 2008 189 635
  
  • Anonymous: "Company profile: History", , 15 December 2010 (2010-12-15), XP055280436, Retrieved from the Internet: URL:http://web.archive.org/web/20101215224 148/http://www.nippon-zoki.co.jp/e/company /enkaku.html [retrieved on 2016-06-14]
  • TAKASHI KUDO ET AL: "Antinociceptive effects of neurotropin in a rat model of central neuropathic pain: DSP-4 induced noradrenergic lesion", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 503, no. 1, 30 July 2011 (2011-07-30) , pages 20-22, XP028287906, ISSN: 0304-3940, DOI: 10.1016/J.NEULET.2011.07.056 [retrieved on 2011-08-06]
  • IYAKUHIN TENPU BUNSHO NEUROTROPIN-JO 4 TAN'I February 2012, XP008179191
  • IYAKUHIN TENPU BUNSHO NEUROTROPIN CHUSHAEKI 1.2 TAN'I February 2012, XP008179277
  • CHAVAN MM ET AL.: 'Increased sialylation and defucosylation of plasma proteins are early events in the acute phase resp' GLYCOBIOLOGY. vol. 15, no. 9, 27 April 2005, pages 838 - 848, XP055253027
  • SHUN'ICHI YAMAYA ET AL.: 'Neuraminic acid (Sialic acid)' JAPANESE JOURNAL OF CLINICAL MEDICINE vol. 62, no. SUPPL., 28 November 2004, pages 614 - 615, XP008179188
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

[Technical Field]



[0001] The present invention relates to a process for producing a pharmaceutical preparation containing an extract from inflamed skins of rabbits inoculated with vaccinia virus wherein the quality is more stabilized by confirming by such a means of tests or inspections that it contains a predetermined amount of N-acetylneuraminic acid.

[Background Art]



[0002] Drug is approved for its manufacture and distribution only after its quality is warranted. In Japan, that is stipulated in Article 14 of the Pharmaceutical Affairs Law. In view of the characteristics of a drug, such a management is basically same in other countries as well. The reason why warranty of the quality is important for a drug as such is that the quality guarantees efficacy and safety of a drug. Conversely, with regard to a drug for which no quality is warranted, neither efficacy nor safety is guaranteed therefore whereby such a one is not competent as a drug.

[0003] In Japan, a material substance being used for the production of a drug and able to be an active ingredient of a drug is called a "drug substance". The same as in a drug, a drug substance is also necessary that its quality is warranted. That is because the quality of a drug depends upon the quality of a drug substance. Incidentally, according to Japanese laws and regulations related to pharmaceutical affairs, a drug substance is stipulated as a drug which is exclusively used for the manufacture of other drug and, in terms of the definition therefore, a drug substance is covered by a drug. However, in the present application, a medicament and a drug substance may be sometimes separately referred to for the sake of convenience and, in such a case, the meaning of a drug shall exclude a drug substance.

[0004] It is general that, when a drug or a drug substance is manufactured by a predetermined manufacturing method, that having a predetermined quality is manufactured. Accordingly, in order to maintain the quality of a drug or a drug substance, manufacture control is also important. For such a purpose, there has been stipulated "Ministerial Ordinance concerning the Standards for Manufacture Control and Quality Control of Drugs and Quasi-Drugs" in Japan. This ministerial ordinance is called GMP (abbreviation of Good Manufacturing Practice) in Japan as well. In GMP, for example, "manufacture control" and "quality control" of drugs are stipulated. In "manufacture control", there is adopted such a way of thinking that the quality is maintained by controlling the material preparation and the manufacturing steps from the initial to the final stages thereof. "Quality control" has been mainly conducted by means of confirmation of the tests and inspections conducted after the manufacture whether the manufactured drug or drug substance actually has predetermined quality standards. When the result of the tests and inspections does not satisfy the previously stipulated standards, then e.g. shipment, distribution and use of the drug and drug substance are not allowed. As such, the quality of drugs and drug substances are controlled by means of the manufacture control and the quality control.

[0005] An extract from inflamed skins of rabbits inoculated with vaccinia virus (hereinafter, it will be sometimes referred to as "the present extract") is an extract containing a non-proteinous active substance extracted and separated from the inflamed skin tissues of rabbits by the inoculation of vaccinia virus. Although the present extract is liquid in an extracted state, it is also possible to make into a solid by means of drying.

[0006] As will be mentioned later, a preparation containing the present extract as an active ingredient (hereinafter, it will be sometimes called "the present preparation") is very useful as a drug. Since the present extract is an active ingredient of the present preparation in that case, the present extract is a drug substance of the present preparation. In a specific product as the present preparation which is manufactured and distributed by the applicant, there is "a preparation containing an extract from inflamed skins of rabbits inoculated with vaccinia virus" (trade name: NEUROTROPIN [registered trade mark]; hereinafter, it will be referred to as "NTP preparation"). In NTP preparation, there are injection (hereinafter, it will be referred to as "NTP injection") and tablet (hereinafter, it will be referred to as "NTP tablet") and both belong to an ethical drug. An extract from inflamed skins of rabbits inoculated with vaccinia virus (hereinafter, it will be referred to as "NTP extract") which is an active ingredient of NTP preparation is a drug substance of NTP preparation. NTP extract is covered by the present extract while NTP preparation (NTP injection and NTP tablet) is covered by the present preparation.

[0007] Indications of NTP injection are "low back pain, cervicobrachial syndrome, symptomatic neuralgia, itchiness accompanied by skin diseases (eczema, dermatitis, urticaria), allergic rhinitis and sequelae of subacute myelo-optico-neuropathy (SMON) such as coldness, paresthesia and pain". Indications of NTP tablet are "postherpetic neuralgia, low back pain, cervicobrachial syndrome, periarthritis scapulohumeralis and osteoarthritis". NTP preparation has been created and developed as a drug by the applicant. NTP preparation has been appreciated for its excellent advantage for efficacy and safety, sold for many years and established a firm position in the Japanese pharmaceutical market. At present, NTP preparation is being exported to China and sold under a trade name of "

/ NEUROTROPIN". Indications of NTP preparation in China are the same as those in Japan.

[0008] The use of Neurotropin in the treatment of neuropathic pain diseses is also described in CA-A-2 792 085 and in T. Kudo et al., Neuroscience Letters, 503, 20-22 (2011).

[0009] As such, the present preparation is very useful as a drug and the present extract is also very useful as a drug substance for the present preparation. However, as mentioned already, the present extract is extracted and separated from the inflamed skin tissues of rabbit by the inoculation of vaccinia virus. Therefore, the present extract contains quite a lot of substances (components) and the present preparation manufactured using the present extract also contains quite a lot of substances (components). Accordingly, it is a very important matter how to control the quality of the present extract and preparation in a stable one.

[0010]  Many of drugs are the preparations containing one or two to three substances (components) at the largest as an active ingredient and, usually, such substances are the chemically synthesized compounds. Therefore, when the content of the compound(s) in said preparation is measured and a predetermined content is contained, the quality of said preparation in view of the content of the active ingredient(s) is guaranteed. However, the extract is an extract from inflamed skin tissues of rabbits by the inoculation of vaccinia virus and contains quite many kinds of substances. It goes without saying that the present preparation where the present extract is an active ingredient also contains quite many kinds of substances. Thus, in the present extract and preparation, specific one or several kind(s) of substance(s) is/are not the active ingredient(s) as such whereby it is not possible to conduct a quality control as in the case of conventional drug where active ingredient(s) is/are specified as substance(s). Therefore, quantitative determination for active ingredient(s) of the present extract and preparation manufactured by the applicant or of NTP extract and NTP preparation is being carried out by such a method where the biological activity (titer) thereof is measured.

[0011] Said method is a biological test method where an analgesic coefficient is determined using SART-stressed (repeated cold stressed) animals which are chronic stressed animals showing a lowered pain threshold than normal animals (Folia Pharmacologica Japonica, vol. 72, no. 5, pages 573-584, 1976). In accordance with the method in this literature, the analgesic coefficient is determined by conducting an analgesic test according to a Randall-Selitto method using SART-stressed (repeated cold stressed) animals. In this method, an analgesic effect is measured using a pressure weight as an index where the pressure stimulation is applied to the tail of mouse and the mouse shows an escape reaction. An analgesic coefficient is a value where the pressure weight measured after administration of a drug is divided by the value before the administration. In NTP extract and NTP preparation, the case where an analgesic coefficient showed more than a predetermined value defined by the applicant is judged to be positive for an analgesic effect and the rate of the numbers of animals judged to be positive is determined and used as an analgesic efficacy rate (%). This value is used and ED50 value is determined from the result upon measurement of standard preparation diluted to various concentrations. "Neurotropin Unit (NU)" which is a unit of biological activity (titer) using for NTP preparation by the applicant is defined that the activity of 1 mg of the present extract where the ED50 value is the dose of 100 mg/kg is 1 Neurotropin unit. ED50 value for each NTP preparation is measured and compared with that of the standard preparation whereupon an analgesic activity (active ingredient content) is quantitatively determined. Hereinafter in the present application, the word "unit" is used as a measure of the active ingredient content (titer) of the present extract and preparation and it is substantially in the same meaning as "Neurotropin Unit" used for NTP extract and NTP preparation.

[0012] In the meanwhile, it is stipulated that the present extract and preparation or NTP extract and NTP preparation manufactured by the applicant are to be subjected to the following plural identity tests in addition to the above-mentioned quantification of the analgesic activity and should conform to them. Thus, with regard to the present extract and preparation manufactured by the applicant, not only the above-mentioned biological activity (titer) is used for guaranteeing the appropriateness of the manufactured lots but also the following plural identity tests are carried out and adaptation thereto is used as a necessary condition for use and shipment of the present extract and preparation.

▪ Identity test of amino acids by a liquid chromatographic method

▪ Identity test of ultraviolet absorbing substances by Ultraviolet-visible Spectrophotometry

▪ Identity test of phosphorus by a color reaction method

▪ Identity test of nucleic acid base by a liquid chromatographic method

▪ Identity test of inhibitory action for the production of kallikrein-like substance by an in vitro test method



[0013] However, even when such tests are carried out, it is not always true that e.g. the amino acids, ultraviolet absorbing substances, phosphorus, and nucleic acid bases, which are objects of the tests are the crucial effective ingredients of the present extract and preparation. Moreover, in those tests, the identity test for amino acids, ultraviolet absorbing substances, phosphorus and nucleic acid bases is a qualitative test which merely confirms the presence of e.g. mino acids. which are objects of the tests and does not check how much amount is contained therein. Even under such circumstances however, those tests are still obligatory for the applicant in order to receive an approval for the manufacture of drugs from the government as a means for reducing the variations in the quality among the manufacturing lots and for guaranteeing the uniform quality in both of the present extract and preparation where the effective ingredients are unidentified.

[0014] Generally speaking, it is advantageous for persons who manufacture an extract from living organisms such as animals and plants or a preparation containing said extract as an active ingredient if and when the standards to which said preparation should conform are small in numbers since time, labor and cost for the test and the inspection are saved and possibility where the manufactured product does not conform to the standard is low. However, in view of guaranteeing the quality of the above extract and preparation, it is desirable that the standard as such is stipulated more strictly. Under such circumstances, the applicant has extensively investigated the new appropriate standard to which the present extract and preparation manufactured by the applicant should conform whereupon the present invention has been achieved. Thus, the amount of N-acetylneuraminic acid contained in the present extract and preparation is measured and, when the amount is within a predetermined range, it is treated that the present extract and preparation as such are appropriately manufactured or, in other words, their use and shipment are permitted. As a result, the variations among manufacturing lots of the present extract and preparation are further reduced and the quality thereof becomes more stable. Further, as a result, efficacy and safety of the present extract and preparation are guaranteed more strictly. If and when there is the present extract or preparation wherein the amount of N-acetylneuraminic acid is out of the stipulated range, it is treated as an adulterated product (a substandard product) whereby it is possible to control the quality of the present extract and preparation in a more stable manner. Thus, it is now possible to stipulate an autonomous or a public standard concerning the amount of N-acetylneuraminic acid contained in the present extract or preparation. In the meanwhile, the applicant has not stipulated a standard for the amount of N-acetylneuraminic acid contained in an NTP extract and an NTP preparation manufactured up to now and has not conducted such an act that the amount is measured and that, after confirming the measured amount is within a predetermined range, the corresponding NTP extract and NTP preparation are, for example, used and shipped.

[0015] As to the documents which disclose the present extract or preparation, CN-A-1205233, WO 2004/060381 and CN-A-1613305 are available. They disclose the content of amino acids and nucleic acid bases in the present extract or preparation. Further, with regard to the present extract or preparation, there is a disclosure for the content of silicons in JP-A-07-097336. However, in the above Patent Documents, there is no disclosure at all how much a specific substance which is N-acetylneuraminic acid is contained in the present extract or preparation. It further goes without saying that, in those documents, there is neither disclosure nor suggestion at all to adopt the content of N-acetylneuraminic acid in the present extract or preparation as an index for the quality control of the present extract or preparation in more a stable manner.

[Summary of the Invention]


[Problems to be solved by the invention]



[0016] As mentioned above, no single substance is identified as an active ingredient in the present extract and preparation. Therefore, quality of the present extract and preparation is guaranteed by e.g. a titer test according to a biological test determining the analgesic coefficient using SART-stressed mice or plural identity tests. Even by the means as such, it is still unavoidable that various components contained in the present extract and preparation permissibly vary for each manufacturing lot. However, since the present preparation is used as a drug for treating the diseases, it is desirable that the quality thereof is to be as constant as possible. It is very meaningful that the quality of the present extract and preparation is warranted to be more stable since it makes efficacy and safety of the present extract and preparation more constant.

[Means for Solving the Problems]



[0017] The present invention is to warrant the quality of the described extract and preparation using the amount of N-acetylneuraminic acid contained therein as an index. Thus, based on the above, the present invention provides a process for producing a pharmaceutical preparation containing an extract from inflamed skins of rabbits inoculated with vaccinia virus, wherein the amount of N-acetylneuraminic acid contained in the preparation is
  1. (i) if the pharmaceutical preparation is an injectable preparation, ≥ 4800 ng per ml of the liquid extract present in the pharmaceutical preparation, or
  2. (ii) if the pharmaceutical preparation is a tablet,
    ≥ 16000 ng per tablet of the pharmaceutical preparation,
    the process comprises
    • preparing an extract from inflamed skin of rabbits inoculated with vaccinia virus;
    • preparing a pharmaceutical preparation containing the extract and being present in the form of an injectable preparation or a tablet; and
    • measuring the amount of N-acetylneuraminic acid contained in the preparation of each manufacturing lot and confirming the content thereof to be as defined above.


[0018] Preferably, in the present process the amount of N-acetylneuraminic acid in the injectable preparation is 4800-27000 ng per ml of the injectable preparation, or the amount of N-acetylneuraminic acid in the tablet is 16000-90000 ng per tablet. Also, in the present process the pharmaceutical preparation is an analgesic agent, and more preferably a therapeutic agent for non-inflammatory pain disease.

[Advantages of the Invention]



[0019] The present extract and the present preparation are such ones which contain predetermined amounts of N-acetylneuraminic acid. As a result thereof, it is possible to treat that the present extract and the present preparation are appropriately manufactured. The present invention contributes in such a matter that the quality of the present extract and preparation is warranted in a more stable manner and efficacy and safety of the present extract and preparation become more constant.

[Mode for Carrying Out the Invention]



[0020] N-Acetylneuraminic acid is a kind of sialic acid. Sialic acid is a generic name for acyl derivatives of neuraminic acid. Although there are many kinds of sialic acids in nature, N-acetylneuraminic acid is the most abundant one among them and the next abundant one is N-glycolylneuraminic acid. Sialic acid is widely distributed in living bodies as a constituting component of e.g. glycoprotein, glycolipid and glycopeptide and it is particularly present on the cell membrane surface of animals or bacteria and plays an important role of biological functions such as participation in specific recognition mechanism of cells. Sialic acid is also considered to be important in medical and pharmaceutical viewpoints as a substance participating in e.g. cancer, inflammation, immune, viral infection, cell differentiation and hormone receptors. Various studies have been conducted for sialic acid-containing biological components and also for sialic acid and derivatives thereof.

[0021] With regard to said sialic acid and particularly to N-acetylneuraminic acid, the applicant has quite surprisingly found that said substance has an analgesic action and particularly an effect for non-inflammatory pain diseases such as neuropathic pain disease and, on the basis of such a finding, the applicant obtained patents (JP-B-4005115 and CN-B-101600438). Since the characteristic of NTP preparation manufactured and distributed by the applicant is also a treating effect for e.g. neuropathic pain disease, N-acetylneuraminic acid is a rational substance (component) as an index for a strict control of the quality of the present extract and the present preparation in a more stable manner.

[0022] Next, a method for manufacturing the present extract and the present preparation will be illustrated.

[0023] The present extract can be prepared by such a manner that inflamed skin tissues of rabbits by the inoculation of vaccinia virus are collected, crushed and processed by adding an extraction solvent thereto, tissue fragments are removed therefrom, a treatment for removal of protein (deproteinization) is carried out, the resulting one is adsorbed with an adsorbent under an acidic condition and then an active ingredient is eluted under a basic condition therefrom.

[0024] Vaccinia virus used herein may be in any strain. Examples thereof include Lister strain, Dairen strain, Ikeda strain, EM-63 strain and New York City Board of Health strain.

[0025] With regard to a rabbit, any rabbit may be used so far as it belongs to Lagomorpha. Examples thereof include Oryctolagus cuniculus, domestic rabbit (domesticated Oryctolagus cuniculus), hare (Japanese hare), mouse hare and snowshoe hare. Among them, it is appropriate to use domestic rabbit. In Japan, there is family rabbit called "Kato" which has been bred since old time and frequently used as livestock or experimental animal and it is another name of domestic rabbit. There are many breeds in domestic rabbit and the breeds being called Japanese white and New Zealand white are advantageously used.

[0026] As to basic extracting steps for the present extract, the following steps are used for example.
  1. (A) Inflamed skin tissues of rabbits by the intradermal inoculation with vaccinia virus are collected, and the inflamed tissues are crushed. To the crushed tissues an extraction solvent such as water, phenol water, physiological saline or phenol-added glycerin water is added to conduct an extracting treatment for several days. Then, the mixture is filtrated or centrifuged to give a crude extract (filtrate or supernatant) wherefrom tissue fragments are removed.
  2. (B) The crude extract obtained in (A) is adjusted to acidic pH, heated and then filtered or centrifuged to conduct a deproteinizing treatment. After that, the deproteinized solution is adjusted to basic pH, heated and then filtered or centrifuged to give a deproteinized filtrate or supernatant.
  3. (C) The filtrate or the supernatant obtained in (B) is adjusted to acidic pH and adsorbed with an adsorbent such as activated carbon or kaolin.
  4. (D) An extraction solvent such as water is added to the adsorbent obtained in (C), the mixture is adjusted to basic pH and the adsorbed component is eluted to give an extract from inflamed skins of rabbits inoculated with vaccinia virus (the present extract).


[0027] The above is the basic steps and each of the steps will be more specifically illustrated as follows.

About (A):



[0028] The inflamed skin tissues of rabbits by the intradermal inoculation of vaccinia virus are collected. The collected skin tissues are washed and disinfected using, for example, a phenol solution. This inflamed skin tissues are crushed and an extraction solvent in 1- to 5-fold thereof by volume is added thereto. Here, the term "crush" means to finely break down into minces using e.g. a mincing machine. As to the extraction solvent, there may be used, for example, distilled water, physiological saline or weakly acidic to weakly basic buffer, and bactericidal/antiseptic agent such as phenol, stabilizer such as, for example, glycerin, or salts such as sodium chloride, potassium chloride or magnesium chloride, may be appropriately added thereto. At that time, it is also possible that the cell tissue is destroyed by a treatment such as freezing/melting, ultrasonic wave, cell membrane dissolving enzyme or surfactant so as to make the extraction easier. The resulting suspension is allowed to stand for 5-12 days. During that period, the suspension may be heated at 30-45°C with or without appropriate stirring. The resulting liquid is subjected to a treatment for separating into solid and liquid (e.g. filtered or centrifuged) to remove the tissue fragments whereupon a crude extract (filtrate or supernatant) is obtained.

[0029] About (B) The crude extract obtained in (A) is subjected to a deproteinizing treatment. The deproteinization may be carried out by a known method which has been usually conducted and a method such as heating treatment, treatment with a protein denaturant (such as acid, base, urea, guanidine or an organic solvent including acetone), isoelectric precipitation or salting-out may be applied. After that, a common method for the removal of insoluble matters such as filtration using filter paper (such as cellulose or nitrocellulose), glass filter, Celite or Seitz filter, ultrafiltration or centrifugation is conducted to give a filtrate or a supernatant wherefrom the separated insoluble protein is removed.

About (C)



[0030] The filtrate or supernatant obtained in (B) is adjusted to acidic or, preferably, to pH 3.5-5.5 to conduct an operation of adsorbing with an adsorbent. Examples of the usable adsorbent include activated carbon and kaolin. An adsorbent is added to the extract followed by stirring or the extract is passed through a column filled with an adsorbent so that the active ingredient can be adsorbed with the adsorbent. When an adsorbent is added to the extract, the adsorbent with which the active ingredient is adsorbed can be obtained by means of e.g. filtration or centrifugation to remove the solution.

About (D)



[0031] For elution (desorption) of the active ingredient from the adsorbent obtained in (C), an elution solvent is added to said adsorbent and adjusted to basic or, preferably, to pH 9-12, elution is conducted at room temperature or with suitable heating, or with stirring, and then the adsorbent is removed by a common method such as filtration or centrifugation. As to the extraction solvent used therefore, there may be used a basic solvent such as water, methanol, ethanol or isopropanol adjusted to basic pH or an appropriate mixed solvent thereof and preferably, water adjusted to pH 9-12 may be used. Amount of the extracting solvent may be appropriately set. In order to use the eluate obtained as such as a drug substance, the pH is appropriately adjusted to e.g. nearly neutral whereby an extract from inflamed skins of rabbits inoculated with vaccinia virus (the present extract) can be finally obtained.

[0032] Since the present extract is liquid at the stage of being prepared, it is also possible that said extract is appropriately concentrated or diluted to make into a desired concentration. When a preparation is manufactured from the present extract, it is preferred to apply a sterilizing treatment with heating. For making into an injection preparation, it is possible to add, for example, sodium chloride so as to prepare a solution being isotonic to physiological saline. It is also possible that the present extract in a liquid state is subjected to an appropriate operation such as concentration to dryness whereby a solid preparation for oral administration such as tablet is manufactured. Specific methods for the manufacture of solid preparation for oral administration from the present extract are disclosed in the specifications of JP-B-3,818,657 and JP-B-4,883,798. The present preparation includes, for example, an injection preparation and a solid preparation for oral administration, prepared as such.

[0033] The content of N-acetylneuraminic acid in the present extract and the present preparation can be measured by the usual quantifying method. To be more specific, there may be used, for example, a measuring method using liquid chromatograph mass spectrometer (LC-MS) or capillary electrophoretic mass spectrometer (CE-MS), a fluorescence labeling method using DMB (1,2-diamino-4,5-methylenedioxybenzene) and an enzymatic method. In any of those methods, N-acetylneuraminic acid in the present extract and preparation can be quantified using a calibration curve prepared by an N-acetylneuraminic acid specimen for calibration.

[0034] The content of N-acetylneuraminic acid contained in the present extract and preparation manufactured by the applicant was measured by the above methods. As a result, although there were some scatters, the present extract and preparation contained 4000 ng or more of N-acetylneuraminic acid per unit. To be more specific, the present extract and preparation contained 4000-18000 ng of N-acetylneuraminic acid per unit. Accordingly, when quality of the present extract and preparation is controlled using the content of N-acetylneuraminic acid in the present extract and preparation as an index, it was judged to be possible to adopt the content as such as a standard. In the meanwhile, when variations happened in the method for the manufacture of the present extract and preparation, the applicant confirmed that the content of N-acetylneuraminic acid per unit may be lower than 4000 ng.

[0035] As will be apparent from the above-mentioned explanation, the term "per unit" used herein means per the content of the active ingredient in the present extract and preparation. The present extract (NTP extract) manufactured by the applicant contains 1.2 units/mL of the active ingredient. The present preparation for injection (NTP injection) manufactured using the same also contains 1.2 unit/mL of the active ingredient. In NTP injection, the injection where the volume is 3 mL and 1 mL are available. Accordingly, a preparation of 3 mL contains 3.6 units of the active ingredient and a preparation of 1 mL contains 1.2 units of the active ingredient. On the other hand, the present preparation for oral administration (NTP tablet) manufactured by the applicant contains 4 units of the active ingredient per tablet.

[0036] Incidentally, the present extract may be concentrated or diluted. Further, the present preparation containing various units may be also manufactured. In such cases, the amount of the active ingredient contained in a unit amount (such as per mL, per mg, per ampoule or per tablet) of the present extract and preparation may also vary. Therefore, it is basically meaningful that the content of N-acetylneuraminic acid is stipulated in relation to the amount of the active ingredient of the present extract and preparation. That is because such a thing is connected to the relation to efficacy and safety of the present extract or preparation. Accordingly, the applicant stipulated the content of N-acetylneuraminic acid in the present extract and preparation in terms of "per the content of the active ingredient" ("per unit"). On the other hand, since the applicant actually manufactures and distributes NTP preparation, it is also certainly meaningful to stipulate per mL or per ampoule of the specific injection or to stipulate per tablet in relation to the dose whereby such stipulation was also adopted.

[0037] In the meanwhile, in NTP injection, there are generic drugs or similar drugs (hereinafter, they will be referred to as "other company's injections") manufactured by the companies other than the applicant's company (hereinafter, they will be referred to as "other companies") in Japan and in China. For other company's injections, an extract from inflamed skins of rabbits inoculated with vaccinia virus (the present extract) which is an active ingredient is also quantitatively determined by using its analgesic effect as an index using SART stress mice. In terms of the indication, the content of the active ingredient in other company's injections is merely mentioned as "unit" in plural other company's injections in Japan which are "ROSEMORGEN Inj." (registered trade mark), "NABUTOPIN Inj." (registered trade mark) and "NOLPORT Inj." (registered trade mark), or is mentioned as "Analgecine unit" or "AGC unit" in one other company's injection in China which is "

/ANALGECINE" (registered trade mark). However, the same as NTP injection, in any of said preparations, the content of the active ingredient is 1.2 units or 1.2 Analgecine (1.2 AGC) units per mL or 3.6 units or 3.6 Analgecine (3.6 AGC) units per ample of 3 mL preparation. To sum up, the "Neurotropin unit" used by NTP preparation and the "unit" or "Analgecine unit" used by other companies are the same measure for stipulating the content of the active ingredient, and they are different just in terms of the expression. Under such circumstances, "unit" is used in the present application in expressing the content of the present extract which is an active ingredient not only for NTP preparation but also for all other company's injections. As such, where the amount of an extract from inflamed skins of rabbits inoculated with vaccinia virus which is an active ingredient is expressed by using "unit" in plural preparations. Therefore, with regard to said preparations, the expression in terms of "unit" is clear for persons skilled in the art.

[0038] As will be apparent from the above, "the present preparation" in the present application is a conception including NTP preparation (NTP injection and NTP tablet) and other company's injections. When other companies will manufacture and distribute tablets (hereinafter, it will be referred to as "other company's tablets") as generic drug or similar drug for NTP tablet in future, the above conception also covers other company's tablets as such.

[0039] As hereunder, specific examples for the manufacture of the present extract and preparation and for the result of measurement of the content of N-acetylneuraminic acid in the present extract and preparation are shown as Examples.

[Examples]


Example 1 (Manufacture of the present extract)



[0040] Skins of healthy adult rabbits were inoculated with vaccinia virus intradermally and the inflamed skins were cut and collected. The collected skins were washed and disinfected by a phenol solution, an excessive phenol solution was removed and the residue was crushed. A phenol solution was added thereto and mixed therewith and the mixture was allowed to stand for 3-7 days, and further heated at 35-40°C together with stirring for 3-4 days. After that, an extracted solution obtained by a solid-liquid separation was adjusted to pH 4.5-5.2 with hydrochloric acid, heated at 90-100°C for 30 minutes and filtered to remove protein. The filtrate was adjusted to pH 9.0-9.5 with sodium hydroxide, heated at 90-100°C for 15 minutes and subjected to a solid-liquid separation.

[0041] The resulting deproteinized solution was adjusted to pH 4.0-4.3 with hydrochloric acid, activated carbon in an amount of 2% to the mass of the deproteinized solution was added thereto and the mixture was stirred for 2 hours and subjected to the solid-liquid separation. Water was added to the collected activated carbon followed by adjusting to pH 9.5-10 with sodium hydroxide and the mixture was stirred at 60°C for 90-100 minutes and centrifuged to give a supernatant. Water was added again to the activated carbon precipitated upon the centrifugation followed by adjusting to pH 10.5-11 with sodium hydroxide and the mixture was stirred at 60°C for 90-00 minutes and centrifuged to give a supernatant. Both supernatants were combined and neutralized with hydrochloric acid to give the present extract.

Example 2 (Method for measuring the content of N-acetylneuraminic acid)



[0042] The content of N-acetylneuraminic acid in the present extract and preparation was measured as follows using a high-performance liquid chromatographic mass spectrometer (LC-MS).

[0043] The present extract (1.2 units/mL) manufactured according to Example 1 was diluted with water to an extent of 10-fold and injected into the LC-MS.

[0044] The present preparation (NTP injection) manufactured using the present extract which was manufactured according to Example 1 was also diluted with water to an extent of 10-fold and injected into the LC-MS.

[0045] With regard to the present preparation (NTP tablet) manufactured using the present extract which was manufactured according to Example 1, three tablets thereof were washed with 3 mL of methanol/chloroform (1:1) for three times to remove the film coat layer, dried, suspended in 12 mL of water (1 unit/mL). After centrifugation of the suspension, the supernatant was diluted with water to an extent of 10-fold and injected into the LC-MS.

[0046] With regard to N-acetylneuraminic acid, a standard solution in an aqueous solution was prepared and a calibration curve was produced.

[0047] In the LC-MS, the 1100 Series manufactured by Agilent Technologies, Inc. and API 3000 (manufactured by Applied Biosystems/MDS Sciex) were used for an HPLC part and a mass spectroscope, respectively. Analytical conditions are as follows.

[0048] Column: Inertsil ODS-3 (ø 2.1 × 150 mm)
Column temperature: 25°C; flow rate: 200 µL/minute
Mobile phase: methanol/0.05% formic acid
Methanol %/minute: 0/0-0/1-44/8-100/8.1-100/11
Injection amount: 5 µL; temperature set for the sample chamber: 4°C
Detection: positive ion detecting MRM

[0049] Measuring conditions for the LC-MS are shown in Table 1. Each parameter in Table 1 means as follows.

▪ DP: voltage applied to orifice plate

▪ FP: voltage applied to focus ring

▪ CE: collision energy

▪ CXP: voltage applied to the outlet of Q2

▪ NEB: pressure of nebulizer gas

▪ CUR: pressure of curtain gas

▪ IS: voltage of ion spray

▪ CAD: pressure of collision gas

▪ TEM: turbo gas temperature

[Table 1]
Detected Ion (Q1/Q3)DPFPCECXPNEBCURISCADTEM
310/274 20 100 20 20 12 10 5000 8 450

Example 3 (Measured result of the content of N-acetylneuraminic acid in the present extract)



[0050] Result of measurement of the content of N-acetylneuraminic acid in the present extract by the method mentioned in Example 2 is shown in Table 2. Content of the active ingredient in the present extract is 1.2 units/mL. The content of N-acetylneuraminic acid in the present extract is expressed in both terms of per unit of the present extract ("/unit") and per mL of the present extract ("/mL"). Incidentally, the references A-C in lot numbers show the difference in the manufacturing places (institutions) of the applicant. Measured values were adjusted to three significant figures (Hereinafter, the above is the same for all of measured values.).
[Table 2]
Lot No.Content of N-acetylneuraminic acid
(ng/unit)(ng/mL)
A01 9920 11900
A02 9670 11600
A03 5980 7180
B01 7490 8990
B02 7360 8830
B03 8420 10100
B04 6830 8200
B05 7690 9230
B06 10100 12100
B07 8420 10100
B08 8830 10600
B09 12000 14400
B10 11700 14000
C01 8060 9670
C02 9250 11100
C03 9580 11500
C04 8920 10700
C05 9250 11100
C06 10800 13000
C07 9750 11700
C08 10500 12600
C09 9170 11000
C10 6290 7550
C11 7800 9360
C12 7490 8990
C13 11800 14200
C14 11400 13700
C15 10200 12200
C16 6750 8100
C17 8750 10500
C18 9500 11400
C19 7540 9050
C20 9670 11600
C21 9750 11700
C22 13400 16100
C23 6800 8160
C24 7420 8900
C25 8670 10400
Mean 9020 10800

Example 4 (Measured result 1 of the content of N-acetylneuraminic acid in the present preparation)



[0051] The result of measurement of the content of N-acetylneuraminic acid in NTP injection (containing 1.2 units per mL) among the present preparation by the method mentioned in Example 2 is shown in Table 3. The result is shown in terms of the content per unit of the active ingredient of the present preparation ("/unit"), per mL of the present preparation ("/mL") and per ampoule containing 3 mL ("/ampoule").
[Table 3]
Type of the present preparation (Identification No.)Content of N-acetylneuraminic acid
(ng/unit)(ng/mL)(ng/ampoule)
NTP injection (NI01) 7450 8940 26800
NTP injection (NI02) 8420 10100 30300
NTP injection (NI03) 6540 7850 23600
NTP injection (NI04) 9500 11400 34200
NTP injection (NI05) 9580 11500 34500
NTP injection (NI06) 10400 12500 37500
Mean 8650 10400 31200

Example 5 (Measured result 2 of the content of N-acetylneuraminic acid in the present preparation)



[0052] The result of measurement of the content of N-acetylneuraminic acid in NTP tablet (containing 4 units per tablet) among the present preparation by the method mentioned in Example 2 is shown in Table 4. The result is shown in terms of the content per unit of the active ingredient ("/unit") and per tablet ("/tablet").
[Table 4]
Type of the present preparation (Identification No.)Content of N-acetylneuraminic acid
(ng/unit)(ng/tablet)
NTP tablet (NT01) 12600 50400
NTP tablet (NT02) 4780 19100
NTP tablet (NT03) 10500 42000
NTP tablet (NT04) 8700 34800
NTP tablet (NT05) 10200 40800
NTP tablet (NT06) 9840 39400
NTP tablet (NT07) 9650 38600
NTP tablet (NT08) 8950 35800
NTP tablet (NT09) 9490 38000
NTP tablet (NT10) 7740 31000
NTP tablet (NT11) 8090 32400
NTP tablet (NT12) 9380 37500
NTP tablet (NT13) 6990 28000
Mean 8990 36000

Comparative Example 1 (Measured result of the content of N-acetylneuraminic acid in other company's injections)



[0053] The result of measurement of the content of N-acetylneuraminic acid in other company's injections by the same manner as in NTP preparation is shown in Table 5. Incidentally, the distribution of "ROSEMORGEN Inj." has been already finished at the stage of filing the present application and is not available in the market and the following measured result is a result of measurement for the thing which was formerly purchased by the applicant in the market.
[Table 5]
Type of other company's injections (Lot No.)Content of N-acetylneuraminic acid
(ng/unit)(ng/mL)
ROSEMORGEN Inj. (2E27B) 141 169
ROSEMORGEN Inj. (4E57A) 142 170
NOLPORT Inj. (678405) 72.8 87.4
NOLPORT Inj. (709203) 305 366
NABUTOPIN Inj. (BD597E) 54.2 65.0
NABUTOPIN Inj. (KF606E) 170 204
ANALGECINE (20071209) 378 454
ANALGECINE (20080301) 377 452


[0054] From the above results, it is noted that, even in the same preparation of the extract from inflamed skins of rabbits inoculated with vaccinia virus, the content of N-acetylneuraminic acid is greatly different depending upon the manufacturing company (Tables 3-5). It is further noted that, even in the preparation of the same company including the applicant, the content of N-acetylneuraminic acid is sometimes considerably different (Tables 3-5). For an extract from inflamed skins of rabbits inoculated with vaccinia virus which is a drug substance for the preparation of the extract from inflamed skins of rabbits inoculated with vaccinia virus, those drug substances of other companies are not available whereby only that which was manufactured by the applicant (NTP extract) was measured. It is noted that, for such a one, there are also scatters to some extent in the content of N-acetylneuraminic acid (Table 2).

[0055] However, in the present extract and the present preparation manufactured by the applicant, N-acetylneuraminic acid was contained in an amount of not less than 4000 ng/unit (Tables 2-4). Further, in the present extract and the present preparation manufactured by the applicant, N-acetylneuraminic acid was contained within a range of 4000-22500 ng/unit. On the contrary, among the present preparation manufactured by other companies, none of them contained such a high amount of N-acetylneuraminic acid (Table 5). Although it is not clear what is the cause for the difference in the contents of N-acetylneuraminic acid in the present preparation manufactured by each of the companies, it is strongly presumed to be caused by the difference in the manufacturing method for the present preparation in each company. Anyway, as mentioned already, N-acetylneuraminic acid has an analgesic action or, particularly, an effect for non-inflammatory pain diseases such as neuropathic pain disease whereby the applicant understands that the fact itself that this substance (component) is contained in more amount in the present preparation (NTP injection) manufactured by the applicant as compared with the injections by other companies constitutes the characteristic and is a favorable characteristic.

[0056] As mentioned hereinabove, it is the characteristic of the present extract and the present preparation that not less than 4000 ng/unit of N-acetylneuraminic acid is contained in the present extract and the present preparation. Similarly, it is the characteristic of the present extract and the present preparation that, when the measurement is done by the measuring method of the content of N-acetylneuraminic acid in the present extract and the present preparation (injection and tablet) mentioned in Example 2 (hereinafter, it will be referred to as "10-fold dilution method"), N-acetylneuraminic acid is contained within a range of 4000-15000 ng/unit in the present extract and the present preparation. It constitutes the characteristic of the present extract and the present preparation that N-acetylneuraminic acid is contained within a range of 4000-22500 ng/unit when the content of N-acetylneuraminic acid in the present extract and the present preparation is measured by a measuring method using other dilution ratio such as 50-fold dilution or 250-fold dilution with water (hereinafter, it will be referred to as a "different dilution method") instead of 10-fold dilution method where the dilution ratio with water is 10-fold. The reason why the upper limit hereinabove is 1.5 times more as compared with the case of 10-fold dilution method will be mentioned later.

[0057] Further, with regard to the injection containing 1.2 units per mL (hereinafter, it will be referred to as "the present injection") among the present preparation, it constitutes the characteristic of the present injection that not less than 4800 ng/mL of N-acetylneuraminic acid is contained therein. Similarly, it constitutes the characteristic of the present injection that, when measurement is done by the 10-fold dilution method, N-acetylneuraminic acid is contained within a range of 4800-18000 ng/mL. It constitutes the characteristic of the present injection that, when the content of N-acetylneuraminic acid in the present injection is measured by a different dilution method, N-acetylneuraminic acid is contained within a range of 4800-27000 ng/mL. Further, when the present injection is that filled with 3 mL volume in an ampoule (hereinafter, the present injection as such will be referred to as "the present injection of 3 mL ampoule"), it constitutes the characteristic of the present injection of 3 mL ampoule that N-acetylneuraminic acid is contained in an amount of not less than 14400 ng per ampoule. Similarly, it constitutes the characteristic of the present injection of 3 mL ampoule that, when measurement is done by a 10-fold dilution method, N-acetylneuraminic acid is contained within the range of 14400-54000 ng/ampoule. It constitutes the characteristic of the present injection of 3 mL ampoule that, when the content of N-acetylneuraminic acid in the present injection of 3 mL ampoule is measured by a different dilution method, N-acetylneuraminic acid is contained within the range of 14400-81000 ng/ampoule. The reason why the upper limit hereinabove is 1.5 times more as compared with the case of the 10-fold dilution method will be also mentioned later.

[0058] Further, with regard to the tablet containing 4 units per tablet (hereinafter, it will be referred to as "the present tablet") among the present preparation, it constitutes the characteristic of the present tablet that not less than 16000 ng/tablet of N-acetylneuraminic acid is contained therein. Similarly, it constitutes the characteristic of the present tablet that, when measurement is done by the 10-fold dilution method, N-acetylneuraminic acid is contained within the range of 16000-60000 ng/tablet. It constitutes the characteristic of the present tablet that, when the content of N-acetylneuraminic acid in the present tablet is measured by a different dilution method, N-acetylneuraminic acid is contained within the range of 16000-90000 ng/tablet. The reason why the upper limit hereinabove is 1.5 times more as compared with the case of the 10-fold dilution method will be also mentioned later.

[0059] In view of the above, it is possible that the content of N-acetylneuraminic acid contained in the present extract and the present preparation is measured so as to confirm whether the present extract and the present preparation are appropriately manufactured whereby the quality thereof is controlled. Thus, it is possible that, when the content of N-acetylneuraminic acid contained in the present extract and the present preparation is measured and, if it is found to be 4000 ng/unit or more, that is evaluated as being appropriately manufactured. It is further possible to conclude that the present extract and the present preparation are appropriately manufactured by means of such a confirmation that, when the content of N-acetylneuraminic acid contained in the present extract and the present preparation is measured by the 10-fold dilution method or by different dilution methods and is found to be 4000-15000 ng/unit or 4000-22500 ng/unit, respectively.

[0060] In the case of the present injection, it can be judged that the present injection is appropriately manufactured when the content of N-acetylneuraminic acid contained in the present injection is measured and is found to be 4800 ng/mL or more. It is further possible to judge that the present injection is appropriately manufactured by measuring the content of N-acetylneuraminic acid contained in the present injection by a 10-fold dilution method or by a different dilution method and by confirming to be 4800-18000 ng/unit or 4800-27000 ng/unit, respectively. Similarly, in the case of the present injection of 3 mL ampoule, it is also possible to judge that the 3 mL ampoule injection is appropriately manufactured when the content of N-acetylneuraminic acid contained therein is measured and is found to be 14400 ng/mL or more or when it is 14400-54000 ng/unit or f 14400-81000 ng/mL in the case of measurement by a 10-fold dilution method or by a different dilution method, respectively.

[0061] In the case of the present tablet, it can be evaluated that, when the content of N-acetylneuraminic acid contained in the present tablet is measured and is found to be 16000 ng/tablet or more, the said tablet is judged to be appropriately manufactured. It is further possible that, when the content of N-acetylneuraminic acid contained in the present tablet is measured by a 10-fold dilution method or by a different dilution method and is confirmed to be 16000-60000 ng/unit or 16000-90000 ng/tablet, respectively, then the said present tablet is judged to be appropriately manufactured.

[0062] Incidentally, the fact that the value corresponding to the upper limit when the above content of N-acetylneuraminic acid is shown in terms of the range of from lower limit to upper limit as measured by a different dilution method is considerably high (about 1.5 times as much) as compared with the measured result (Tables 2-4) obtained in Examples 3-5 is due to the following reason and grounds.

[0063] Thus, in the above Examples, the content of N-acetylneuraminic acid is measured by means of LC-MS, and N-acetylneuraminic acid is apt to be affected by impurity ions (ion suppression). Basically, the present inventors measure a sample of e.g. the present extract, after diluting to an extent of 10-fold but, when diluted to an extent of 50-fold or 250-fold, higher values were sometimes noted than the measured values in the case of the 10-fold dilution. It is likely that such a phenomenon is due to the fact that, in case the dilution degree is high, the affection by the concentration of impurity ions lowers. As a result of inspection by the present inventors comparing the quantified values in various dilution degrees in plural samples, it was confirmed that, upon dilution to an extent of 50-fold or 250-fold, the value of about 1.5 times in maximum as compared with the case of 10-fold dilution was observed (Table 6). Based upon such a fact, the value corresponding to the upper limit of the content of N-acetylneuraminic acid was set as mentioned above in the present application.
[Table 6]
Identification No. or Lot No.Content of N-acetylneuraminic acid
(ng/unit) 10-fold dilution sample(ng/unit) 50-fold dilution sample(ng/unit) 250-fold dilution sample
A01 9920 10400 9830
A01 9670 10700 9750
A02 5980 6210 6460
B09 12000 13300 12700
B10 11700 13200 13900
C24 7420 8030 8100
C25 8670 10200 9750
NTP injection (NI04) 9500 12200 11300
NTP injection (NI05) 9580 12500 11400
NTP injection (NI06) 10400 13500 13800
NTP tablet (NT03) 10500 14100 12000
NTP tablet (NT04) 8700 12300 11200
NTP tablet (NT05) 10200 13900 13000
NTP tablet (NT06) 9840 13200 12300
NTP tablet (NT07) 9650 12300 11600
NTP tablet (NT08) 8950 11400 10700
NTP tablet (NT09) 9490 12000 11900
NTP tablet (NT10) 7740 9640 10000
NTP tablet (NT11) 8090 11300 10400
NTP tablet (NT12) 9380 11900 11800
NTP tablet (NT13) 6990 8990 8700

[Industrial Applicability]



[0064] As mentioned hereinabove, the present invention provides a process for producing a pharmaceutical preparation containing an extract from inflamed skins of rabbits inoculated with vaccinia virus or a preparation containing the extract which is deemed to be appropriately manufactured by such a means that the content of N-acetylneuraminic acid is measured so that the fact of containing a predetermined amount therein is confirmed. The present invention also provides an inspection method by which the extract and the preparation is deemed to be appropriately manufactured by means of confirming that each manufacturing lot of the extract contains a predetermined amount of N-acetylneuraminic acid. Since the extract and the preparation as such are manufactured using biological tissues, it is now possible to warrant the quality thereof for each lot in more strictly whereby that is very useful.


Claims

1. A process for producing a pharmaceutical preparation containing an extract from inflamed skins of rabbits inoculated with vaccinia virus, wherein the amount of N-acetylneuraminic acid contained in the preparation is

(i) if the pharmaceutical preparation is an injectable preparation, ≥ 4800 ng per ml of the liquid extract present in the pharmaceutical preparation, or

(ii) if the pharmaceutical preparation is a tablet, ≥ 16000 ng per tablet of the pharmaceutical preparation,
the process comprises

- preparing an extract from inflamed skin of rabbits inoculated with vaccinia virus;

- preparing a pharmaceutical preparation containing the extract and being present in the form of an injectable preparation or a tablet; and

- measuring the amount of N-acetylneuraminic acid contained in the preparation of each manufacturing lot and confirming the content thereof to be as defined above.


 
2. The process of claim 1, wherein the amount of N-acetylneuraminic acid in the injectable preparation is 4800-27000 ng per ml of the injectable preparation.
 
3. The process of claim 1, wherein the amount of N-acetylneuraminic acid in the tablet is 16000-90000 ng per tablet.
 
4. The process of any of claims 1-3, wherein the pharmaceutical preparation is an analgesic agent.
 
5. The process of claim 4, wherein the analgesic agent is therapeutic agent for non-inflammatory pain disease.
 


Ansprüche

1. Verfahren zur Herstellung einer pharmazeutischen Zubereitung, die ein Extrakt aus entzündeten Häuten von Kaninchen enthält, welche mit Vaccinia-Virus geimpft sind, worin die Menge an N-Acetylneuraminsäure, die in der Zubereitung enthalten ist

(i) ≥ 4800 ng pro ml des in der pharmazeutischen Zubereitung vorhandenen flüssigen Extrakts beträgt, wenn die pharmazeutische Zubereitung eine injizierbare Zubereitung ist, oder

(ii) ≥ 16000 ng pro Tablette der pharmazeutischen Zubereitung beträgt, wenn die pharmazeutische Zubereitung eine Tablette ist,
das Verfahren umfassend

- Herstellen eines Extrakts aus entzündeten Häuten von Kaninchen, die mit Vaccinia-Virus geimpft sind;

- Herstellen einer pharmazeutischen Zubereitung, welche das Extrakt enthält und in Form einer injizierbaren Zubereitung oder eine Tablette vorhanden ist; und

- Messen der Menge an N-Acetylneuraminsäure, die in der Zubereitung jeder Fertigungscharge enthalten ist, und Bestätigen, dass der Gehalt davon wie oben definiert ist.


 
2. Verfahren gemäß Anspruch 1, worin die Menge an N-Acetylneuraminsäure in der injizierbaren Zubereitung 4800-27000 ng pro ml der injizierbaren Zubereitung beträgt.
 
3. Verfahren gemäß Anspruch 1, worin die Menge an N-Acetylneuraminsäure in der Tablette 16000-90000 ng pro Tablette beträgt.
 
4. Verfahren gemäß mindestens einem der Ansprüche 1-3, worin die pharmazeutische Zubereitung ein Analgetikum ist.
 
5. Verfahren gemäß Anspruch 4, worin das Analgetikum ein Therapeutikum für eine nicht-entzündliche Schmerzkrankheit ist.
 


Revendications

1. Procédé de production d'une préparation pharmaceutique contenant un extrait de peau enflammée de lapins inoculés par le virus de la vaccine, dans lequel la quantité d'acide N-acétylneuraminique présente dans la préparation est

(i) si la préparation pharmaceutique est une préparation injectable, ≥ 4 800 ng par ml de l'extrait liquide présent dans la préparation pharmaceutique, ou

(ii) si la préparation pharmaceutique est un comprimé, ≥ 16 000 ng par comprimé de la préparation pharmaceutique,
le procédé comprend

- la préparation d'un extrait de peau enflammée de lapins inoculés par le virus de la vaccine ;

- la préparation d'une préparation pharmaceutique contenant l'extrait, de type préparation injectable ou comprimé, et

- la mesure de la quantité d'acide N-acétylneuraminique dans la préparation de chaque lot préparé et la confirmation que cette teneur satisfait la définition ci-dessus.


 
2. Procédé selon la revendication 1, dans lequel la quantité d'acide N-acétylneuraminique dans la préparation injectable est 4800 à 27 000 ng par ml de la préparation injectable.
 
3. Procédé selon la revendication 1, dans lequel la quantité d'acide N-acétylneuraminique dans le comprimé est 16 000 à 90 000 ng par comprimé.
 
4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel la préparation pharmaceutique est un agent analgésique.
 
5. Procédé la revendication 4, dans lequel l'agent analgésique est un agent thérapeutique pour douleur non inflammatoire.
 




REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description